Global HA Viscosupplementation Market Opportunities and Forecast 2023-2030

HA Viscosupplementation Market Overview

The global HA Viscosupplementation Market is expected to show significant growth in the forthcoming years. Several factors are increasing the growth ratio of the market. Obesity has become a common health issue among adults and the old age population. Increasing body weight exerts pressure on the lower extremity joints such as the knees. Excessive pressure on the joints leads to joint pain, damage, and orthopedic disorders. Therefore, growing obesity along with its health hazards is projected to boost the growth of the global HA Viscosupplementation Market over the forecast period.  As per WHO data, in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese.

Osteoarthritis is common and the prevalence is high among the old age population. Hence, the rising old age population across the world is a key factor that is expected to propel the growth of the market. Moreover, rising developments in the hyaluronic acid-based therapy for osteoarthritis are increases the adoption and demand for hyaluronic acid viscosupplementation products. This major factor remarkably contributes to the growth of the HA Viscosupplementation market in the coming years.

Furthermore, important factors such as improving health care infrastructure, rising demand for quality care, and rapid urbanization are offering several opportunities to product manufacturers to expand their geographic presence in the market.

Covid-19 Impact on HA Viscosupplementation Market:

In addition, the current HA Viscosupplementation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the HA Viscosupplementation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

HA Viscosupplementation Market Segment Overview

Based on application, the Knee Osteoarthritis segment has the largest share of the market. Knee osteoarthritis is a leading cause of disability among the population across the world. Various treatment options are available to treat osteoarthritis. Viscosupplementation is one of the procedures for osteoarthritis. In addition, main objectives of treating knee osteoarthritis with hyaluronic acid injections are to improve joint movement by increasing joint lubrication and reduce joint friction and inflammation, to slow osteoarthritis progression, and reduce pain. Moreover, according to treatment Type, the Single Injection segment is expected to witness a rise during the forecast period, due to a shorter regimen, reduced hospital visits, and fewer adverse effects and associated pain.

HA Viscosupplementation Market, By Treatment Type

·       Single Injection
·       Multiple Injection

HA Viscosupplementation Market, By Dosage Form

·       Solution
·       Gel

HA Viscosupplementation Market, By Application

·       Knee Osteoarthritis
·       Hip Osteoarthritis
·       Shoulder Osteoarthritis
·       Ankle Osteoarthritis

HA Viscosupplementation Market, By End-user

·       Hospitals
·       Specialty Clinics
·       Ambulatory Surgical Centers

HA Viscosupplementation Market Regional Overview

In terms of region, North America commanded a major share of the global Hyaluronic Acid Viscosupplementation market. This can be mainly attributed to the presence of key players, increasing the demand for advanced products, and a highly developed health care sector in this region. Similarly, the market in the Asia Pacific is projected to expand at a rapid pace during the forecast period. Main factors such as rising awareness, increasing prevalence of osteoarthritis, and growing old age population are anticipated to propel the growth of the market in this region.

HA Viscosupplementation Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

HA Viscosupplementation Market Competitor overview

Some key developments and strategies adopted by manufacturers in HA Viscosupplementation are highlighted below.

·       In March 2019, Seikagaku Corporation announced the launch of HyLink®, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy through MDM S.p.A.

HA Viscosupplementation Market, Key Players

·       Anika Therapeutics, Inc.
·       Ferring B.V.
·       Zimmer Biomet
·       Fidia Pharma USA Inc,
·       Bioventus.
·       LG Chem
·       Sanofi
·       SEIKAGAKU CORPORATION